NCT03813979View on ClinicalTrials.gov

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 15, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
HIV-1-infectionHepatic Impairment
Interventions
DRUG

Dolutegravir

Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach

Sponsors

Collaborators (1)

Erasmus Medical Center
All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

University Medical Center Groningen

OTHER

lead

Radboud University Medical Center

OTHER

NCT03813979 - Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. | Biotech Hunter | Biotech Hunter